|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/4196 | |
| A61K 31/506 | |||
| A61P 31/00 |
| (11) | Number of the document | 1713477 |
| (13) | Kind of document | T |
| (96) | European patent application number | 05702261.8 |
| Date of filing the European patent application | 2005-01-13 | |
| (97) | Date of publication of the European application | 2006-10-25 |
| (45) | Date of publication and mention of the grant of the patent | 2008-10-01 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/IB2005/000098 |
| Date | 2005-01-13 |
| (87) | Number | WO 2005/084671 |
| Date | 2005-09-15 |
| (30) | Number | Date | Country code |
| 0402491 | 2004-02-04 | GB | |
| 545663 P | 2004-02-17 | US |
| (72) |
HUMPHREY, Michael John, GB
|
| (73) |
Pfizer Limited,
Ramsgate Road, Sandwich, Kent CT13 9NJ,
GB
Pfizer Inc., 235 East 42nd Street, New York NY 10017, US |
| (54) | COMBINATION OF VORICONAZOLE AND AN ANTIFUNGAL CYP2C19 INHIBITOR |
| COMBINATION OF VORICONAZOLE AND AN ANTIFUNGAL CYP2C19 INHIBITOR |